Brean Capital assumed coverage on shares of Recro Pharma Inc. (NASDAQ:REPH) in a research note released on Monday. The brokerage issued a buy rating and a $21.00 target price on the specialty pharmaceutical company’s stock.
A number of other equities analysts have also recently commented on the company. Roth Capital assumed coverage on Recro Pharma in a report on Friday, September 16th. They set a buy rating and a $24.00 target price for the company. Janney Montgomery Scott assumed coverage on Recro Pharma in a report on Monday, August 29th. They set a buy rating and a $21.00 target price for the company. Zacks Investment Research raised Recro Pharma from a sell rating to a hold rating in a report on Friday, August 26th. Finally, HC Wainwright reissued a buy rating on shares of Recro Pharma in a report on Monday, July 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $17.55.
Shares of Recro Pharma (NASDAQ:REPH) traded up 1.2677% during midday trading on Monday, hitting $8.8508. The company had a trading volume of 29,292 shares. The company’s market capitalization is $87.35 million. The company has a 50-day moving average of $9.20 and a 200-day moving average of $8.06. Recro Pharma has a 12 month low of $5.59 and a 12 month high of $12.86.
Recro Pharma (NASDAQ:REPH) last announced its earnings results on Thursday, August 11th. The specialty pharmaceutical company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by $0.05. Recro Pharma had a negative net margin of 8.70% and a negative return on equity of 52.80%. The firm had revenue of $17.30 million for the quarter, compared to analyst estimates of $18.70 million. Analysts predict that Recro Pharma will post ($3.13) earnings per share for the current year.
In related news, major shareholder Healthcare Master Fun Broadfin purchased 390,000 shares of the company’s stock in a transaction dated Tuesday, August 16th. The stock was acquired at an average cost of $7.50 per share, for a total transaction of $2,925,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 39.30% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the stock. BlackRock Institutional Trust Company N.A. raised its stake in Recro Pharma by 30.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 49,947 shares of the specialty pharmaceutical company’s stock worth $397,000 after buying an additional 11,682 shares during the period. BlackRock Fund Advisors raised its position in shares of Recro Pharma by 37.5% in the second quarter. BlackRock Fund Advisors now owns 15,268 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 4,163 shares during the last quarter. Stonepine Capital Management LLC raised its position in shares of Recro Pharma by 81.0% in the second quarter. Stonepine Capital Management LLC now owns 428,670 shares of the specialty pharmaceutical company’s stock valued at $3,408,000 after buying an additional 191,796 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Recro Pharma by 0.4% in the second quarter. Vanguard Group Inc. now owns 107,252 shares of the specialty pharmaceutical company’s stock valued at $852,000 after buying an additional 400 shares during the last quarter. Institutional investors and hedge funds own 36.38% of the company’s stock.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.